The 2023 End­points 11; Re­gen­eron’s gene edit­ing am­bi­tions; GSK’s re­search re­vamp; Rip­ple ef­fect of Dana-Far­ber, Brigham breakup; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

While an End­points crew as­sem­bled in Boston for End­points 11, one of our biggest projects of the year, the rest of the team held down the fort and de­liv­ered ex­cel­lent cov­er­age from oth­er cor­ners of the world. We take a look at Re­gen­eron’s bet on gene edit­ing de­liv­ery, GSK’s re­search re­vamp, the im­pact of the breakup be­tween Dana-Far­ber and Brigham and Women’s Hos­pi­tal, no­table start­up launch­es, and more.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER